Human health & EHS
SPECTRA is the EFEIA Research Institute's pillar on people. The program studies how artificial EMF affects the human body, how electrohypersensitivity actually presents in the population, and what kind of evidence the field needs to translate findings into clinical and educational practice.
Most people Mild
Occasional symptoms Moderate
Daily impact Severe
Multi-system response Disabling
Life-altering
The body, under exposure
Artificial EMF is a chronic exposure. People live with it, sleep with it, and work in it. Some report no effect. Others develop a constellation of symptoms (headaches, sleep disruption, cognitive fatigue, dermatologic and cardiac responses) that follow exposure and remit when it stops.
That second group is the population behind electrohypersensitivity. Their experience has been documented for decades, and yet the literature still lacks consistent diagnostic criteria, agreed-upon response profiles, and population-level prevalence data.
SPECTRA exists to close those gaps. The pillar runs an international census of self-reported EHS, develops a risk assessment methodology that informs the BEMCP certification program, builds educational protocols for youth exposure, and prepares the ground for clinical research on response profiles and central sensitization mechanisms.
What our flagship survey found
Five lines of inquiry
Each subproject within SPECTRA targets a different gap in the literature. Three are active and producing results today; two are scoped and ready to launch as funding and clinical partnerships come online.
EHS Global Census
The largest international survey of self-reported electrohypersensitivity that we are aware of. Three nested surveys (A, B, C) capture symptom prevalence, exposure context, and response patterns. A cross-survey cohort of 94 to 96 respondents lets us track how the same individuals describe their experience under different question sets, which is unusual in EHS research.
Youth Exposure Education
Children and adolescents accumulate years of artificial EMF exposure before adulthood, often without informed adult guidance. The program develops educational materials and exposure-reduction protocols for schools, parents, and pediatric clinicians, anchored in the LEDNA framework.
EMF Risk Assessment
A standards-grade methodology for measuring and reporting personal EMF exposure across home, work, and transit environments. The work feeds directly into the BEMCP certification program, where it underpins how the seven evaluation categories define a passing space.
Central Sensitization & EHS
EHS shares clinical features with the central sensitization syndromes (fibromyalgia, irritable bowel, chronic fatigue, multiple chemical sensitivity). This program will investigate the shared neurological mechanisms, asking whether artificial EMF acts as a sensitizing trigger in the same family of multi-system response.
EHS Phenotype Research
Census data has surfaced 8 distinct response profiles within the EHS spectrum. They differ in symptom clustering, severity, and triggering exposures. This project formalizes the typology so clinicians can recognize what they are seeing, and so further research can stratify by profile rather than treating EHS as a single condition.
Distinct response profiles within the EHS spectrum
A single label hides a varied population. Our Census 2025 data has surfaced eight distinct response profiles that differ in which symptoms cluster together, how severe they are, and which exposures trigger them. Recognizing those differences is the first step toward clinical screening that actually fits what patients describe.
How SPECTRA connects to the rest of the Institute
Many EHS reports overlap with hypersensitivity reactions documented in pollinators and livestock. TERRA's apiary work informs how SPECTRA frames non-thermal biological response.
Vehicles are now one of the highest-exposure environments people inhabit. NEXUS supplies the cabin-level measurements that SPECTRA's risk assessment uses to map daily exposure load.
Biophoton emission is one of the few candidate biomarkers that could give EHS an objective signature. LUMINA's instrumentation work would underwrite SPECTRA's clinical research.
Artificial Quantum Noise reframes "exposure" as a non-thermal phenomenon. QUANTIS's theoretical work changes which questions SPECTRA's epidemiology is positioned to answer.
Take part in the next wave of the Census, or work with us on a clinical project
The EHS Global Census stays open. If you live with EHS or treat patients who do, your data and your clinical observations move the field forward. SPECTRA also partners with clinicians, researchers, and educators on the planned response-profile and central sensitization studies.